Advising EuroEyes on its first post-IPO acquisition

• Global
• United Kingdom
• Hong Kong

09-02-2022

Eversheds Sutherland’s Corporate team in Hong Kong advised on the £30m acquisition of LVCP 

Eversheds Sutherland’s Corporate team in Hong Kong has advised EuroEyes International Eye Clinic Limited (EuroEyes), a Hamburg-headquartered company listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1846), on its £30 million acquisition of London Vision Clinic Partners Limited (LVCP).

LVCP is a world-class laser eye surgery clinic based in London, principally engaging in the provision of premium vision correction services including PRK, LASIK, SMILE, phakic lens (ICL) surgery and refractive cataract surgery. The founders of LVCP have won worldwide recognition for their inventions and major contributions to the field of refractive surgery.

The acquisition of LVCP will enable EuroEyes to expand its footprint in the UK and improve the Group’s synergy and bring benefits to the Group’s ophthalmic services.

The deal was announced by EuroEyes on 20 January 2022.

Eversheds Sutherland has an existing relationship with EuroEyes, having advised  on its initial public offering and listing on the Hong Kong Stock Exchange in October 2019. With its plan to use part of the funds raised from its IPO to acquire additional clinic groups in Europe, the acquisition of LVCP is its first post-IPO acquisition.

The Hong Kong Corporate team was led by Partner Dickson Ng throughout the transaction with assistance from Associate Anthony Lam.

Dickson Ng, Partner, commented:

“We are delighted to continue the on-going collaboration with EuroEyes on its first acquisition after its IPO in Hong Kong, and helping EuroEyes to establish a footprint in the UK, which is a new market for the group. Patients would be fortunate to have the experience of EuroEyes surgeons on their doorstep in London."

• Dickson Ng
• Partner
• +852 2186 4921
• +852 2186 4921
• Connect with Dickson Ng on LinkedIn

< Go back